Phenylketonuria, PKU, is caused by deficiency of phenylalanine hydroxylase (PAH) resulting in increased levels of phenylalanine in body fluids. PAH requires the non-protein cofactor BH 4 and the rate-limiting step in the synthesis of BH 4 is GTP cyclohydrolase I (GTP-CH). Here we show that overexpression of the two enzymes PAH and GTP-CH in primary human keratinocytes leads to high levels of phenylalanine clearance without BH 4 supplementation. Integration of multiple PAH and GTP-CH transgenes were achieved after optimized retroviral transduction. Phenylalanine clearance was measured ex vivo in primary human keratinocytes cotransduced with PAH and GTP-CH (more than
Introduction
Increased levels of phenylalanine in the blood and body fluids is the dominating metabolic disturbance in PKU. The first step in the major pathway for catabolizing dietary l-phenylalanine is phenylalanine hydroxylase (PAH; phenylalanine 4-monooxygenase, EC 1.14.16.1) and this pathway accounts for approximately 75% of the disposal of this amino acid. 1 PAH is a tetrameric enzyme mainly expressed in liver, and the catalytic activity requires the cofactor (6R)-L-erythro-5,6,7,8-tetrahydrobiopterin (BH 4 ). The intracellular concentration of BH 4 , which is mainly determined by GTP cyclohydrolase I (GTP-CH, EC 3.5.4.16) activity, determines the activity of PAH. 2 BH 4 is a co-factor for three pteridine-requiring monooxygenases that hydroxylate aromatic l-amino acids, ie tyrosine hydroxylase (TH), tryptophan hydroxylase (TPH), and phenylalanine hydroxylase (PAH), as well as for nitric oxide synthase (NOS). BH 4 is synthesized from guanosine triphosphate (GTP) by GTP-CH, 6-pyruvoyltetrahydropterin synthase (PTS), and sepiapterin reductase (SPD). The rate-limiting enzyme in the synthesis of BH 4 is GTP-CH. 3 In the western world, newborns are screened for hyp- erphenylalaninemia (HPA) and identified patients are treated with a strict diet low in phenylalanine. Within the last 5-10 years, studies have shown that the diet should be lifelong. [4] [5] [6] Discontinuation of the diet as an adult is often associated with progressive loss of intellectual function as well as emotional disturbances. Continued exposure to elevated phenylalanine blood levels is deleterious to brain function, but the pathologic mechanism is not completely understood. It is also an increasing clinical problem that fetuses can be damaged by the increased phenylalanine concentration in untreated pregnant PKU patients (maternal PKU). 7 Somatic gene therapy of PKU has been performed in animal models using PAH gene transfer to liver tissue. [8] [9] [10] Recently, it was shown in the mouse model of PKU, Pah(enu2), that adenovirus-mediated gene transfer into the liver, combined with immunosuppressant treatment to prolong the gene expression, could reverse the hypopigmentation of the skin associated with PKU. 10 It has been hypothesized that circulating phenylalanine might be adequately cleared and disease phenotype influenced by expressing PAH in tissues other than the liver. As a potential target cell T cells have been investigated. 11 It was found that virus-transduced T cells produce higher levels of PAH activity compared with control mock-infected T cells. Furthermore, PAH has been constitutively expressed in skeletal and cardiac muscle of transgenic mice carrying the PAH cDNA under transcriptional control of the mouse muscle creatine kinase promoter. 12 
Gene Therapy
After breeding the muscle PAH-expressing mice and the strain of liver PAH-deficient, hyperphenylalaninemic mice, offspring lacking PAH activity in liver but expressing PAH in muscle were obtained. In these animals serum phenylalanine levels decreased significantly when the mice were supplemented with injections of the cofactor tetrahydrobiopterin (BH 4 ). 12 Therefore, PAH gene therapy targeted to heterologous tissues, such as muscle, might be a possibility in the treatment of PKU. However, lack of local production of BH 4 might be a problem.
A very attractive location for a 'phenylalanine sink' might be the skin. Epidermal keratinocytes synthesize and secrete numerous proteins illustrating their high metabolic capacity. 13 Sophisticated techniques make it possible to cultivate these cells in vitro and generate a multilayered tissue which can be used for transplantation. Retrovirus-mediated gene transfer into keratinocytes can lead to permanent gene expression in vitro, as well as in vivo indicating that also keratinocyte stem cells are targeted by the gene transfer procedures used. 14, 15 Furthermore, the skin is the largest organ in the body with good contact to the blood stream illustrated by the fact that genetically manipulated human keratinocytes can produce and secrete medical relevant proteins to the circulation (human growth hormone, apoE, factor IX). [16] [17] [18] In addition, gene transfer into the skin has been investigated as a treatment modality of ADA deficiency and gyrate atrophy. 19, 20 Here the skin is intended to serve as a 'metabolic sink', detoxifying the body for accumulating metabolites.
In normal skin, both keratinocytes and melanocytes contain phenylalanine hydroxylase activity and also the capacity to synthesize and recycle BH 4 . 21, 22 With the ultimate goal of using genetically modified skin tissue as a 'metabolic sink' in the treatment of PKU we have investigated the capacity of primary human keratinocytes to metabolize phenylalanine. Here we show that retrovirus-mediated co-overexpression of PAH and GTP-CH leads to substantial clearance of phenylalanine without BH 4 supplementation even to levels exceeding that of a human liver cell line (HepG2 cells).
Results
In order to achieve primary human keratinocytes capable of metabolizing phenylalanine, we constructed retroviral vectors expressing PAH and GTP-CH as described in Materials and methods ( Figure 1 ). Two alternative vector designs were constructed differing in having a neo gene downstream of an internal ribosome entry site (IRES). Use of vectors containing the neo gene leads in general to lower titers and lower expression compared with the 'neo-less' vector. 23 The retroviral vectors were packaged in the gibbon ape leukemia virus (GALV) packaging cell line PG13, as described in Materials and methods. PG13 cells producing vectors containing a neo gene were selected in G418. Packaging cells producing vectors without the neo gene were cloned by limiting dilution in 96-well plates to obtain clones with high expression (see Materials and methods). Supernatant from PG13 cells was used to transduce primary human keratinocytes. Keratinocytes were either transduced with one of the retroviral vectors alone or cotransduced with combinations of the two types of retroviral vectors encoding PAH and GTP-CH. As control, the keratinocytes were mock-transduced with a GCsamEN vector without a transgene.
Integration of the transgenes was analyzed by Southern blotting. Genomic DNA from transduced keratinocytes was isolated and digested with NheI. The Southern blot was hybridized with a PAH cDNA or a GTP-CH cDNA probe, respectively. As seen in Figure 2 , transduced keratinocytes resulted in bands with the expected size (GCsamPAH: 4283 bp; GCsamPAHEN: 5666 bp; GCsamGTP-CH: 3072 bp; GCsamGTP-CHEN: 4455 bp). Keratinocytes transduced with GCsamPAH or GCsamGTP-CH resulted in a signal with a higher intensity compared with that obtained from keratinocytes transduced with GCsamPAHEN or GCsamGTP-CHEN, respectively, indicating that more copies are integrated when the 'neo-less' vectors are used. Cotransduction of the keratinocytes leads to integration of both transgenes ( Figure 2 , lanes 6 and 7). Quantification of the Southern blot using a phosphorimager showed that one to three copies of the transgenes were integrated per cell using the GCsamPAH and GCsamGTP-CH vectors.
In order to demonstrate that keratinocytes transduced with GCsamPAH or GCsamPAHEN contained enzymatically active PAH, a PAH enzyme assay was performed. The PAH activity was determined in crude extracts from transduced keratinocytes, as well as in extracts of the human hepatoma cell line HepG2. PAH activity was present in keratinocytes transduced with GCsamPAH and GCsamPAHEN and the amount of activity seems to correlate with the number of integrated transgenes (Table 1) . Cells transduced with GCsamPAH produced higher PAH enzyme activity than cells transduced with GCsamPAHEN. The level of activity in keratinocytes transduced with GCsamPAH was more than three-fold higher than the activity present in HepG2 cells. For comparison, the level of activity in HepG2 cells is approximately 10-15% of the levels observed in normal human liver. 24 The ability of transduced keratinocytes to clear phenylalanine from the culture medium was measured in order to determine whether overexpression of PAH and GTP-CH resulted in enhanced phenylalanine disappearance. Phenylalanine clearance represents a combination of hydroxylation of phenylalanine to tyrosine and incorporation of phenylalanine into new cellular protein. TransGene Therapy duced keratinocytes and HepG2 cells were incubated in cultivation media and the amount of phenylalanine remaining after 24 h was determined. Keratinocytes overexpressing PAH or GTP-CH alone did not result in a phenylalanine clearance exceeding that of mock-transduced keratinocytes ( Figure 3 ). However, keratinocytes overexpressing both PAH and GTP-CH resulted in considerable clearance. Highest clearance was obtained when keratinocytes were cotransduced with GCsamPAH as the first vector followed by transduction with GCsamGTP-CH (214.8 ± 2.9 nmol phenylalanine/24 h/10 6 cells, measured over a period of 24 h). This level exceeds that of the liver cell line HepG2 by 16.5-fold. Including the less efficient vector GCsamPAHEN instead of GCsamPAH in the cotransduction resulted in a lower level of phenylalanine clearance indicating that phenylalanine clearance correlated with the amount of PAH activity. Cocultivation of keratinocytes transduced with GCsamPAH and keratinocytes transduced with GCsamGTP-CH also resulted in significant phenylalanine clearance indicating metabolic co-operation between cells overexpressing PAH and cells overexpressing GTP-CH (Figure 3) .
Tyrosine secretion was measured by incubating transduced keratinocytes and control HepG2 cells in media containing 14 C-phenylalanine at 37°C. After 8 and 24 h the amounts of 14 C-phenylalanine and 14 C-tyrosine in the media was determined as described in Materials and methods ( Figure 4) . As described previously cotransduction of the primary human keratinocytes resulted in phenylalanine clearance at a level higher than HepG2 cells. Concomitantly, the secretion of tyrosine from cotransduced keratinocytes was at higher levels compared with HepG2 cells.
In order to measure the maximal capacity of phenylalanine clearance from cotransduced keratinocytes, the phe- nylalanine concentration was determined in the incubation media after successive incubation periods of 6 h. As can be seen in Figure 5 , phenylalanine clearance remained at a high level over the 48 h of the experiment, and increased even further towards the end of the period (probably due to cell proliferation), in contrast with cells incubated in the same media for this long period of time. The phenylalanine level in the media did not continue to decline beyond 20 h when keratinocytes were incubated in the same media during the entire experiment. This could be due to interfering substances accumulating in the media detected in the fluorometric assay. Based on the results of Figure 5 , it could be calculated that more than 370 nmol phenylalanine/24 h/10 6 cells are cleared in this system.
Discussion
Considering that PAH is mainly expressed in the liver, somatic gene therapy of PKU might naturally be performed using the liver as the target organ. Due to safety issues, however, other tissues are worth considering as well. For a short time application such as gene therapy of maternal PKU, the skin is a very attractive target tissue, since genetically modified skin can easily be removed again. Currently such an approach would involve transferring retroviral vectors into keratinocytes ex vivo followed by transplantation of the modified autologous cells back to the patient.
In the skin both melanocytes and keratinocytes do express PAH and the enzymes necessary to synthesize and recycle BH 4 . 21 However, our experiments show that the endogeneous enzymes are not sufficient to lead to significant uptake and clearance of phenylalanine from the surrounding media.
A 'metabolic sink' composed of genetically modified skin has previously been investigated as a method to treat ADA deficiency and OAT deficiency. 19, 20 These studies identified several problems, showing that for each application it is important to dissect the molecular back-
Figure 5 Time-course of phenylalanine clearance. One milliliter complete keratinocyte medium was incubated at 37°C with keratinocytes transduced with GCsamPAH and GCsamGTP-CH grown to confluency in six-well plates. At the indicated time-points aliquots were removed and used for determining the phenylalanine concentration. Keratinocytes received fresh medium every 6 h () or were incubated in the same media for the entire length of the experiment (᭹). Data are given as the mean of triplicate determinations with the vertical bars.
ground. The capacity of an epidermal graft to clear metabolites is dependent not only on the amount of enzyme produced in the cells, but also on parameters such as cofactor supply, regional substrate concentrations and clearance of downstream metabolites. In OAT deficiency, conversion of accumulated ornithine is taking place intramitochondrially, and the transport of ornithine across the inner mitochondrial membrane might be ratelimiting. In ADA deficiency, the accumulated metabolite, adenosine, is mainly present intracellularly. Thus the amounts of blood that has to be cleared by a 'metabolic sink', that only clears plasma, is unrealistically high. Compared with these diseases, PKU might be a more suitable candidate disease for 'metabolic sink' therapy, since conversion of phenylalanine to tyrosine is taking place in the cytosol, and phenylalanine is present in plasma in a relatively high concentration (PKU patients often display levels of phenylalanine in the plasma exceeding 1000 m). However, as our studies show, overexpression of at least two enzymes, both PAH and GTP-CH, is required to obtain the desired effect.
Due to immunological reactions against gene-manipulated keratinocytes, it has only been possible to achieve limited duration of expression of a foreign protein after transplantation to animals. 25 Immunity should not constitute a problem after transplantation of PAH and GTP-CH-expressing keratinocytes to the majority of PKU patients, since most disease-causing mutations in PAH lead to some residual protein, implying that the immune system should not react against overexpressed PAH enzyme. 26 We have shown that retrovirus-mediated co-overexpression of PAH and GTP-CH leads to substantial clearance of phenylalanine without BH 4 supplementation. This is in accordance with the fact that several studies have shown that GTP-CH overexpression leads to production and secretion of BH 4 . 27, 28 Transfer of the two genes into the same cell was not necessary, since cocultivation of cells transduced with PAH and cells transduced with GTP-CH also resulted in phenylalanine clearance. Thus the experiments indicate metabolic co-operation between cells overexpressing PAH and cells overexpressing GTP-CH at least in culture. Such co-operation has been described before. Thus co-expression of GTP-CH and tyrosine hydroxylase leads to production of L-DOPA, and for this effect it was demonstrated that it was not necessary to overexpress the enzymes in the same cell. 29 Also, double transduction of the GTP-CH and 6-pyruvoyltetrahydropterin synthase (PTS) genes allows PTS-deficient human fibroblasts to synthesize and release BH 4 . 27 We have shown that keratinocytes overexpressing GTP-CH and PAH are able to clear more than 370 nmol phenylalanine/24 h/10 6 cells. Calculating on a per cell basis, a graft of 20 cm × 20 cm (containing 2 × 10 9 metabolically active cells 30 ) should remove more than 0.74 mmol phenylalanine/24 h. This value should be compared with the amount of phenylalanine in a diet: 1.2-3.0 mmol/24 h. 31 Thus combined with diet there might be a window where a skin-based 'metabolic sink' could be of clinical relevance.
Besides potential gene therapy applications, mutations in both GTP-CH and PAH genes might be tested after expression in primary human keratinocytes. Mutations in GTP-CH leading to dopa-responsive dystonia, and disGene Therapy ease-causing mutations in PAH, have mainly been characterized after expression in bacterial expression systems. 32, 33 The developed experimental model system constitutes an alternative, allowing investigations of the effect of mutations in PAH and in GTP-CH in untransformed human cells on the biochemical flux.
Isolation of clones of packaging cell lines producing high titers of 'neo-less' retroviral vectors can be performed in several ways, such as using a dot blot screening method, 34 ELISA of target cells, 35 immunofluorescence of target cells, 36 or other more laborious methods. We present a novel system for screening of a 'neo-less' retroviral clone, based on metabolic flux in a biological system. The advantage is that identified clones are optimized for the desired effect, ie enhanced biochemical phenylalanine uptake.
In our experimental system, competition of accumulated tyrosine on the phenylalanine uptake into cultured keratinocytes might inhibit phenylalanine clearance. These issues might not be limiting factors in vivo. Still several other processes involved in the uptake and conversion of phenylalanine to tyrosine might be rate-limiting. A clear example demonstrated in this study is synthesis and recycling of BH 4 . Genetic manipulation at other points along the metabolic pathway might further enhance phenylalanine conversion and increase the chances of obtaining clinical benefit.
Materials and methods
Cell culture All packaging cell lines and human hepatoma cells (HepG2) (ATCC, Manassas, VA, USA) were cultivated in high glucose (4.5 g/l) Dulbecco's modified Eagle's medium (DMEM, Gibco, Life Technology, Rockville, MD, USA) supplemented with 10% fetal bovine serum (Gibco, Life Technology), 100 U/ml of penicillin and streptomycin (Gibco, Life Technology) and 2 mm of l-glutamine (Gibco, Life Technology). Primary human epidermal keratinocytes were cultivated on a feeder layer of ␥-irradiated NIH 3T3 cells (ATCC) in complete serum containing keratinocyte media (modified from Rheinwald and Green, 37 as described by Wu et al 38 ): Dulbecco's modified Eagle's medium (DMEM, Gibco, Life Technology): Ham's F12 medium (Gibco, Life Technology) 3:1, supplemented with 10% fetal bovine serum (Gibco, Life Technology), 100 U/ml of penicillin and streptomycin (Gibco, Life Technology), 2 mm of lglutamine (Gibco, Life Technology), 0.5 g/ml of hydrocortisone (Calbiochem, San Diego, CA, USA), 1.8 × 10 −4 m of adenine (Sigma, St Louis, MO, USA), 5 g/ml of insulin (Sigma), 10 −10 m of cholera enterotoxin (ICN, Costa Mesa, CA, USA) and 10 ng/ml of EGF (Gibco, Life Technology). To limit potential contribution of feeder cells in the biochemical analysis performed, keratinocytes in cultures used for analysis were confluent. Control experiments showed that feeder cells did not contribute to the biochemical measurements performed.
Retroviral vectors and packaging cell lines
The vectors used in these studies were constructed by cloning the 2.40 kb full-length PAH cDNA phPAH247 (ATCC) or 1.15 kb full-length GTP-CH cDNA, kindly provided by Dr M Gü tlich, Technische Universität Mü nchen, Munich, Germany, and Dr T Nomura, Dept of Pharmacology, Fujita Health University School of Medicine, Toyoake, Japan, into the retroviral vectors GCsam or GCsamEN 39 ( Figure 1 ). In these vectors the expression of the transgenes is driven from a Moloney murine leukemia virus LTR. The GCsamEN retroviral vector contains a neo gene downstream of an internal ribosome entry site (IRES). 39 All vectors were packaged in PG13 as described. 34 DNA was transfected into GP+E86 40 by calcium phosphate co-precipitation (mammalian transfection kit, Stratagene, La Jolla, CA, USA). Supernatant from transfected cells was harvested 24 h later, supplemented with polybrene to a concentration of 8 g/ml, passed through a 0.45 m filter, and used to transduce PG13 cells. One day later PG13 cells transduced with GCsam-PAHEN or GCsamGTP-CHEN were selected in media containing 0.8 mg/ml G418 (Gibco, Life Technology). The titers of the neo-containing vectors measured on Hela cells as G418 colony-forming units (c.f.u.): GCsamEN: 1.1 × 10 6 , GCsamGTP-CHEN: 2 × 10
5
, GCsamPAHEN: 0.8 × 10
5 . PG13 cells transduced with GCsamPAH or GCsamGTP-CH were cloned by limiting dilution in 96-well plates and clones were analyzed for vector production after 15 days.
Transduction of keratinocytes
Transduction of keratinocytes was performed essentially as described, 41 with the exception that a centrifugation step was included to increase the efficiency. Polybrene (8 g/ml) and Hepes-HCl pH 7.4 (20 mm) were added to fresh supernatant from packaging cell lines cultivated at 37°C, and the supernatants were passed through a 0.45 m filter. Keratinocytes, seeded the day before (10 5 cells in each well of a six-well plate containing ␥-irradiated 3T3 cells) were treated with 2 ml of retroviral supernatants (MOI 1-10). Plates were centrifuged 30 min at 32°C at 1000 g and then incubated at 37°C for 1.5 h. Thereafter, the supernatants were removed, and keratinocytes were refed with fresh complete keratinocyte media. Double transduced keratinocytes were obtained by performing each transduction separately on 2 successive days. Transduction of the keratinocytes with a GCsam retroviral vector containing GFP showed that close to 100% of the cells were transduced using this vector. Furthermore, when selecting keratinocytes transduced with a neo-containing vector, there was no apparent difference in the growth between cells cultured with and without G418.
Measurements of PAH enzyme activity
Cell pellets were disrupted in a buffer containing 0.2 m KCl, 0.05 m K 2 HPO 4 (pH 7.0), 1 m DTT, 0.7% Triton X-100 and protease inhibitors (PMSF, leupeptin, aprotenin, and lysozyme) by vortexing repeatedly for 40 min on ice, and centrifuged at 4°C for 25 min at 20 800 g. PAH activity was assayed in vitro by measuring the production of After incubation for 60 min at room temperature, the phenylalanine hydroxylation reaction was stopped by adding excess unlabeled phenylalanine and tyrosine. Proteins were precipitated with TCA and pelleted by centrifugation for 5 min. 14 C-phenylalanine and 14 C-tyrosine were separated on a TLC-plate precoated with cellulose (Merck 1.05730, Whitehouse Station, NJ, USA) in a solution of chloroform:methanol:ammonia (55:35:10) and visualized on a phosphorimager screen. Quantification was done using the software Image Gauge ver 3.11 (Fujifilm, Tokyo, Japan).
Phenylalanine clearance from intact cells Cells were grown to confluency in six-well plates. The cells were allowed to equilibrate for 30 min at 37°C in fresh complete keratinocyte media. The preincubation media was then replaced with 1 ml of fresh complete keratinocyte media and the cells were incubated at 37°C in a 5% CO 2 , humidified air incubator with constant shaking. Aliquots of medium were removed at different timepoints. After the assay was terminated cells were trypsinized and counted. Phenylalanine concentration in the medium samples was measured using a fluorometric assay based on the method of McCaman and Robins 42 utilizing the fact that a fluorescent compound is formed when phenylalanine reacts with ninhydrin (Phenylalanine Kit, Sigma). Keratinocytes were passaged in culture two to five times following transduction at the time the phenylalanine clearance experiments were performed.
Tyrosine secretion was measured essentially as described for phenylalanine clearance using the fluorometric assay except that 1 Ci 14 C(U)-phenylalanine was added to the complete keratinocyte medium. Medium was collected after 8 and 24 h, boiled for 5 min, and centrifuged for 5 min. 14 C-phenylalanine and 14 C-tyrosine were separated on a TLC plate, visualized and quantitated as described above. A confluent well of HepG2 cells contained 7.9 ± 2.9 × 10 6 cells (n = 7) whereas a confluent well of keratinocytes contained 1.1 ± 0.4 × 10 6 cells (n = 7).
Screening of clones producing 'neo-less' PAH vector Supernatants from PG13 clones supplemented with polybrene were transferred to eight-well chamber slide flasks (Nunc, Roskilde, Denmark) containing primary human keratinocytes, seeded the day before at 10 4 keratinocytes and 10 4 ␥-irradiated 3T3 cells per chamber in complete keratinocyte medium. The keratinocytes were incubated at 37°C for 24 h after which the slide flasks were fixed in a 4% formaldehyde solution supplemented with 0.1% Tween-20 at room temperature for 5 min. Slides were incubated with mouse monoclonal anti-PAH antibody (PH8, PharMingen, San Diego, CA, USA) diluted in 5% FCS in PBS for 30 min at room temperature. After washing in PBS, slides were incubated with FiTCconjugated rabbit anti-mouse antibody (Dako, Glostrup, Denmark) diluted in 5% FCS in PBS for 30 min at room temperature. After adding mounting solution (Sigma) containing 2.5% 1,4-diazabicyclo-[2.2.2]octan (Fluka, Seelze, Germany), slides were viewed using a Leica microscope. Nine clones of the 21 tested were positive and selected for further analysis. Keratinocytes transduced with supernatant from uncloned PG13 GCsamGTP-CH packaging cells were seeded in each well of a six-well plate containing ␥-irradiated 3T3 cells. The day after, the keratinocytes were given 2 ml of retroviral supernatant, supplemented with polybrene and HepesHCl pH 7.4, from the nine positive PG13 GCsamPAH clones. When the double-transduced keratinocytes reached confluency the cells were given fresh complete keratinocyte medium. Twenty-two hours later the medium was harvested and the phenylalanine concentration in the medium was determined by the fluorometric assay. The clone giving rise to the highest clearance of phenylalanine was chosen for further experiments.
Screening of clones producing 'neo-less' GTP-CH vector Keratinocytes transduced with supernatant from uncloned PG13 GCsamPAH packaging cells were seeded in each well of a six-well plate containing ␥-irradiated 3T3 cells. The day after the keratinocytes were given 2 ml of retroviral supernatant, supplemented with polybrene and Hepes-HCl pH 7.4, from 20 PG13 GCsamGTP-CH clones and screened by measuring phenylalanine uptake as described above in the procedure for screening clones producing the 'neo-less' PAH vector.
Southern blotting analysis
Southern blotting procedures were performed as described. 43 Genomic DNA from transduced keratinocytes was isolated and digested with the restriction enzyme NheI. Five micrograms of DNA was electrophoresed on a 0.7% agarose gel and blotted to a Magnacharge membrane (Frisenette, Ebeltoft, Denmark). The membrane was hybridized with a 32 P random labelled PAH cDNA probe derived from phPAH247 or with a 32 P random labelled GTP-CH cDNA probe.
